Humanised monoclonal antibody drug leronlimab has shown ‘impressive results’ in a small observational Covid-19 study, said the drug’s developer CytoDyn CEO Dr Nader Pourhassan in a conference call.
Originally developed to treat HIV, the drug is a CCR5 antagonist that inhibits viral entry. It is undergoing Phase II clinical trials as a treatment for HIV and secured fast-track designation from the US Food and Drug Administration (FDA).
Go deeper with GlobalData
The drug’s ability to mitigate cytokine storm is the basis for its study as a potential Covid-19 treatment.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
